Janus Henderson Group Ltd. filed Amendment No. 5 to its Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,119,413 common shares of Monopar Therapeutics Inc., representing 16.7% of the class as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Janus Henderson Group Ltd. reported beneficial ownership of 1,119,413 common shares of Monopar Therapeutics Inc.
  • Percent of class: The 1,119,413 shares represent 16.7% of the outstanding common shares, according to the filing.
  • Voting and dispositive power: Janus Henderson reported 0 shares with sole voting or sole dispositive power, and 1,119,413 shares with both shared voting power and shared dispositive power.
  • Event date: The date of the event requiring this filing was September 30, 2026.
  • Filer classification: Janus Henderson Group Ltd. is identified as a parent holding company (type HC), organized in Jersey, with a principal office at 201 Bishopsgate, EC2M 3AE, United Kingdom.
  • No individual portfolio exceeds 5%: According to the filing, none of the Managed Portfolios individually own more than five percent of the common shares of Monopar Therapeutics Inc.

Janus Henderson's Amendment 5 Ownership Disclosure for Monopar Therapeutics

According to the Schedule 13G filing (Amendment No. 5) submitted on November 16, 2026, and listed under NASDAQ:MNPR, Janus Henderson Group Ltd. disclosed that it is the ultimate parent of multiple SEC-registered investment advisers and foreign equivalents, collectively referred to in the filing as "Asset Managers." These include entities such as Janus Henderson Investors US LLC, Victory Park Capital Advisors LLC, and Richard Bernstein Advisors LLC, among others named in the filing.

The filing states that the Asset Managers "generally exercise investment and/or voting discretion on behalf of their clients," which include investment companies, institutional separate accounts, and retail separate accounts, collectively described as "Managed Portfolios." As a result of this discretion, the Asset Managers "may be deemed to be the beneficial owner of 1,119,413 common shares of Monopar Therapeutics, Inc." The filing further notes that the Asset Managers "do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights." The right to receive dividends and sale proceeds belongs to the Managed Portfolios themselves.

The filing was signed by Kristin Mariani, identified as Head of North America Compliance at Janus Henderson Group Ltd., and certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing references Exhibit 99 for identification and classification of the relevant subsidiary under Item 7.

What Was Disclosed

Janus Henderson Group Ltd. filed Amendment No. 5 to its Schedule 13G disclosing beneficial ownership of 1,119,413 common shares of Monopar Therapeutics Inc., equal to 16.7% of the class, with all voting and dispositive power held on a shared basis as of September 30, 2026.